(Q81707177)

English

Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report

scientific article published on 26 July 2008

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Takumi Kawaguchi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Shuji Sumie

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Minoru Itou

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Eitaro Taniguchi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Tsunetaka Matoba

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Michio Sata

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

26 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

54

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

690-694

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18661237%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

https://scigraph.springernature.com/pub.10.1007/s10620-008-0397-5

0 references

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side effects of alpha interferon in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current state of interferon therapy for chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of hepatitis C: patients with cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of chronic viral hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18661237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81707177&oldid=1753701300"